Private UK Medical Cannabis Prescriptions Near 2 Million in Year, Sparking Safety Warnings
A surge in private medical cannabis prescriptions across the UK has prompted health experts to reiterate warnings over patient safety and clinical oversight.
By The Global Wire Newsroom · Reported from David Churchill
Link preview · horizonglobalnews.com
Private UK Medical Cannabis Prescriptions Near 2 Million in Year, Sparking Safety Warnings
A surge in private medical cannabis prescriptions across the UK has prompted health experts to reiterate warnings over patient safety and clinical oversight.
Private healthcare providers in the United Kingdom dispensed nearly two million prescriptions for medical cannabis over a 12-month period ending in May, according to reporting by David Churchill. The total of 1,967,268 prescriptions handed out by commercial clinics highlights a dramatic expansion of the private medical cannabis sector over the past three years. The rapid rise has drawn heightened concern from medical experts and clinical specialists, who have repeatedly warned about the potential health risks, variable quality of oversight, and commercial incentives associated with high-volume private prescribing.
Key facts
What happened
Data highlighted in reporting by David Churchill reveals that private clinics issued 1,967,268 prescriptions for cannabis-based medicinal products in the UK during the 12-month period to May. This figure marks a significant escalation in private sector activity compared to earlier years, reflecting a expanding commercial infrastructure dedicated to processing patient consultations and fulfilling prescriptions for unlicensed medicinal cannabis.
In the UK healthcare ecosystem, patients seeking medical cannabis predominantly access treatment through specialized private clinics operating online or through physical consultations. Patients undergo private clinical evaluations, pay out-of-pocket assessment fees, and fund their ongoing monthly prescriptions. The prescribed products typically include imported dried cannabis flower, oral oils, sublingual sprays, and capsules containing varying ratios of tetrahydrocannabinol (THC) and cannabidiol (CBD).
While NHS prescribing pathways remain tightly controlled, the private sector has established a direct-to-consumer model that caters to broad clinical presentations. The steep volume of prescriptions—approaching two million within a single annual cycle—indicates that private clinics are managing hundreds of thousands of active prescription cycles for British patients, prompting renewed scrutiny from professional medical bodies regarding consultation thoroughness and long-term treatment monitoring.
Why it matters
The rapid growth of private medical cannabis prescribing has significant implications for public health, healthcare economics, and regulatory oversight in the United Kingdom.
From a clinical perspective, the widespread availability of high-potency cannabis preparations outside of NHS control raises concerns regarding adverse health outcomes. Medical professionals frequently cite risks such as cognitive impairment, potential exacerbation of underlying psychiatric conditions—including psychosis and severe anxiety—and the development of cannabis use disorder. Because many cannabis-based products are prescribed as unlicensed special medicines, they have not undergone the rigorous, phase-three randomized controlled trials required for standard pharmaceutical licensing, leaving long-term efficacy and safety profiles uncertain.
From a healthcare system standpoint, the figures underscore a widening divide between public and private medicine. Patients unable to secure treatment through the NHS due to stringent clinical criteria are turning to private clinics, creating an equity issue where access to treatment depends heavily on personal financial resources. Conversely, critics argue that commercial incentives within private clinics may lower the threshold for prescribing, potentially leading to over-prescribing for conditions where conventional treatments have not been fully exhausted.
Furthermore, the influx of nearly two million private prescriptions challenges regulatory agencies responsible for inspecting private healthcare providers, monitoring doctor conduct, and auditing drug distribution channels across the country.
The background
The current framework governing medical cannabis in the United Kingdom originated in November 2018, when the UK government rescheduled cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001. The policy shift followed high-profile public campaigns involving pediatric patients with severe, drug-resistant epilepsy, whose families sought legal access to cannabis oils.
Under the 2018 legislative change, cannabis was moved from Schedule 1—which designates controlled substances with no recognized medicinal value—to Schedule 2. This legal reclassification empowered GMC-registered specialist doctors to prescribe cannabis-based medicinal products (CBPMs) to patients under their care, provided the decision fell within their specialist area of registration.
However, integration into the publicly funded NHS has remained minimal. Guidance issued by the National Institute for Health and Care Excellence (NICE) established strict evidence requirements for NHS recommendations. NICE approved cannabis-based medications for only a limited range of conditions, specifically severe forms of childhood epilepsy (such as Dravet syndrome and Lennox-Gastaut syndrome), spasticity related to multiple sclerosis, and intractable nausea or vomiting caused by chemotherapy.
Due to the high cost of products and a lack of extensive clinical trial data demonstrating cost-effectiveness, local NHS commissioning bodies rarely approve funding outside these specific parameters. As a result, fewer than a few hundred patients have received NHS-funded prescriptions since 2018. This restrictive public access created a market opportunity for private healthcare entrepreneurs, leading to the rapid proliferation of specialized private cannabis clinics across England, Scotland, Wales, and Northern Ireland.
Reaction
The publication of the prescription figures has reinforced existing divisions between medical bodies, regulatory institutions, and patient advocacy organizations.
Medical associations and psychiatric specialists have repeatedly urged caution regarding the rapid scale of private prescribing. Representatives from Royal Colleges and mental health professionals point out that increased exposure to cannabis products, particularly formulations with high concentrations of THC, carries established risks of triggering mental health episodes in vulnerable individuals. Clinical experts argue that private consultations must not bypass rigorous psychiatric screening or long-term risk assessments.
Patient advocacy groups and industry bodies offer a different perspective, arguing that private clinics provide essential relief to individuals suffering from chronic pain, movement disorders, and treatment-resistant illness. Advocates contend that high prescription numbers reflect substantial unmet medical need across the population, which public healthcare services have failed to address due to restrictive funding guidelines.
Regulatory authorities, including the Care Quality Commission (CQC) in England and equivalent health oversight bodies in the devolved administrations, monitor private clinics to ensure compliance with fundamental care standards. The General Medical Council (GMC) continues to emphasize that doctors prescribing unlicensed medicines hold high personal responsibility to ensure the treatment is clinically appropriate, safe, and supported by appropriate record-keeping.
What we don't know yet
Despite the specific prescription totals reported, several critical data points regarding private medical cannabis prescribing remain unavailable to the public:
Understanding these missing elements is necessary to assess whether current private prescribing practices align with safe clinical standards or present unmanaged public health risks.
What to watch
Key developments and upcoming decisions will determine how regulators and lawmakers respond to the expansion of private medical cannabis prescribing:
This report is based on reporting by David Churchill on medical cannabis prescription statistics in the United Kingdom.
How this story was produced
This report was written by The Global Wire newsroom from reporting first published by David Churchill. We verify the core facts against the original report, write our own account, and add the background and consequences a short wire item leaves out. Drafting is AI-assisted inside an editor-supervised pipeline, and every story is checked for accuracy of attribution, structure and duplication before it appears — full detail in our AI and funding disclosure.
Spotted an error? Tell us at corrections@horizonglobalnews.com and read our corrections policy or editorial standards.
Reader comments
Loading comments…